These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19825933)

  • 41. Anderson-Fabry disease: enzyme replacement therapy.
    Leon-Mateos A; Fernández-Redondo V; Beiras A; Toribio J
    Acta Derm Venereol; 2004; 84(1):88-9. PubMed ID: 15040494
    [No Abstract]   [Full Text] [Related]  

  • 42. Fabry disease--whom to treat and when.
    Mehta A
    Clin Ther; 2008; 30 Suppl B():S43-4. PubMed ID: 18395136
    [No Abstract]   [Full Text] [Related]  

  • 43. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
    Frustaci A; Russo MA; Chimenti C
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
    [No Abstract]   [Full Text] [Related]  

  • 44. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fabry disease in an oligosymptomatic male.
    Altarescu G; Elstein D
    Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
    [No Abstract]   [Full Text] [Related]  

  • 46. Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry's disease during enzyme-replacement therapy.
    Prinz C; Farr M; Hering D; Horstkotte D; Faber L
    Clin Res Cardiol; 2010 Jan; 99(1):53-5. PubMed ID: 19774328
    [No Abstract]   [Full Text] [Related]  

  • 47. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
    Senocak Tasci E; Bicik Z
    Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Fatal outcome of a patient with Fabry disease in enzymatic treatment].
    Moyano MJ; del Toro N; Amor J; Milán JA
    Nefrologia; 2005; 25(2):207-8. PubMed ID: 15912661
    [No Abstract]   [Full Text] [Related]  

  • 49. [Results of enzyme replacement therapy in Fabry disease nephropathy].
    Dussol B
    Presse Med; 2007 Mar; 36 Spec No 1():1S43-7. PubMed ID: 17546767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rare diseases in Croatia--lesson learned from Anderson-Fabry disease.
    Mrsić M; Nola M
    Croat Med J; 2008 Oct; 49(5):579-81. PubMed ID: 18925690
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data.
    Dehout F; Schwarting A; Beck M; Mehta A; Ricci R; Widmer U;
    Acta Paediatr Suppl; 2003 Dec; 92(443):14-5; discussion 5. PubMed ID: 14989460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease, who died after 2.5 years of enzyme replacement. Virchows Arch. 2005 Nov 29; 1-7.
    Politei J
    Virchows Arch; 2006 Jun; 448(6):873. PubMed ID: 16523259
    [No Abstract]   [Full Text] [Related]  

  • 53. Enzyme replacement therapy of Fabry disease.
    Clarke JT; Iwanochko RM
    Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New products highlight ambiguity of orphan drug law.
    Reid B
    Nat Biotechnol; 2003 Jan; 21(1):6-7. PubMed ID: 12511896
    [No Abstract]   [Full Text] [Related]  

  • 56. PR interval and the response to enzyme-replacement therapy for Fabry's disease.
    Waldek S
    N Engl J Med; 2003 Mar; 348(12):1186-7. PubMed ID: 12646684
    [No Abstract]   [Full Text] [Related]  

  • 57. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adaptive pathway development for Fabry disease: a clinical approach.
    Schuller Y; Arends M; Körver S; Langeveld M; Hollak CEM
    Drug Discov Today; 2018 Jun; 23(6):1251-1257. PubMed ID: 29455022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Orphan drugs and sick patients].
    Kristiansen IS; Olsen JA
    Tidsskr Nor Laegeforen; 2005 Apr; 125(8):992. PubMed ID: 15852066
    [No Abstract]   [Full Text] [Related]  

  • 60. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.